Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) insider Sushil Patel sold 15,575 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $18.05, for a total value of $281,128.75. Following the completion of the transaction, the insider now directly owns 154,571 shares of […]
Letko Brosseau & Associates Inc. cut its holdings in Replimune Group, Inc. (NASDAQ:REPL – Get Rating) by 67.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,525 shares of the company’s stock after selling 15,275 shares during the period. […]
18.05.2023 - Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track ...
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]
Piper Sandler restated their overweight rating on shares of Replimune Group (NASDAQ:REPL – Get Rating) in a research note published on Monday morning, Benzinga reports. The firm currently has a $44.00 target price on the stock. A number of other brokerages have also commented on REPL. HC Wainwright boosted their price objective on Replimune Group […]